

Singleron extends reach outside China, strengthens expertise in translational & clinical research

08 March 2022 | News

China-based Singleron acquires Proteona



Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, has announced the acquisition of Proteona Pte. Ltd., a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe.

By acquiring Proteona's existing network throughout greater Asia, Europe, the US and Canada, the acquisition strengthens Singleron's position outside China and provides Singleron access to Proteona's technologies for single-cell multi-omic analysis and expertise in generating insights for the Biopharmaceutical market.

Founded in 2017 by Jonathan Scolnick, Gene Yeo, and Shawn Hoon, Proteona specializes in combining single-cell proteogenomic analysis with machine learning methods to identify novel biomarkers and generate machine-learning based predictive models of disease severity and therapeutic response. To support these efforts Proteona has developed innovative methods for single-cell multi-omic analysis and data interpretation. These include tools such as MapCell™ for cell annotation and MapBatch™ for batch correction that have significant advantages over conventional single-cell based methods for data analysis.